Versant Capital Management’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
Other funds holding TRDA
BBA
Versant Capital Management's TRDA Position: Q3 2026 in Review
Versant Capital Management reduced its Entrada Therapeutics (TRDA) stake by 0.38% in Q3 2026, selling an estimated $111 and leaving 4,205 shares worth $26.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1795.
Versant Capital Management first reported a position in TRDA in Q2 2025 and has held it in 6 quarters since. The position peaked at $51.1K in Q1 2026. 129 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.
- Versant Capital Management held 4,205 shares of Entrada Therapeutics worth $26.7K as of Q3 2026.
- Versant Capital Management sold 16 Entrada Therapeutics shares in Q3 2026, an estimated $111.
- Entrada Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1795 holding.
- Versant Capital Management first reported a position in Entrada Therapeutics in Q2 2025 and has held it in 6 quarters since.
- Versant Capital Management's Entrada Therapeutics position peaked at $51.1K in Q1 2026.
- 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.
Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.